Shimla Online

DelveInsight’s, “Sepsis Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Sepsis pipeline landscape.

“Sepsis Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Sepsis Pipeline Report

• DelveInsight’s Sepsis Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Sepsis treatment.
• Leading Sepsis Companies Cidara Therapeutics, Vivacelle Bio, SciClone Pharmaceuticals, Asahi Kasei Pharma, Sanofi, Shionogi, Revimmune, Inotrem, Enlivex Therapeutics, Abionyx, and Others are evaluating Sepsis drugs candidate to improve the treatment landscape.
• The promising Sepsis Therapies in the pipeline included such as Drotrecogin alfa, sPLA2 Inhibitor, Interleukin-7, and others
• The Sepsis Pipeline Report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage.
• The Sepsis Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Latest Breakthrough and Developments in the Sepsis Treatment Landscape

• The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin. Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis.
• VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body’s fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Request a Sample Copy and discover the recent advances in Sepsis Pipeline Report @ Sepsis Pipeline Outlook

Sepsis Overview

Sepsis is a life-threatning organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Implementing preventive measures against infections, such as good hygiene practices, ensuring access to vaccination programs, improved sanitation and water quality and availability, and other infection prevention and control best practices both in the community and health care settings, are key steps in reducing the occurrence of sepsis.

Sepsis Emerging Drugs

• Rezafungin: Cidara Therapeutics
• VBI-S: Vivacelle Bio

Sepsis Pipeline Therapeutics Analysis

There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics.

Learn more about the novel and emerging Sepsis pipeline therapies @ Sepsis Clinical Trials

DelveInsight’s Sepsis Pipeline Report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sepsis Route of Administration

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Sepsis Molecule Type

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Sepsis Pipeline Report

• The report provides detailed insights about emerging therapies for Sepsis treatment and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Sepsis Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sepsis market.

The Sepsis Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.

For further information on the Sepsis Pipeline therapeutics, reach out to “Sepsis Drugs”

Scope of the Sepsis Pipeline Report

• Coverage- Global
• Sepsis Companies- Cidara Therapeutics, Vivacelle Bio, SciClone Pharmaceuticals, Asahi Kasei Pharma, Sanofi, Shionogi, Revimmune, Inotrem, Enlivex Therapeutics, Abionyx, and others
• Sepsis Therapies- Drotrecogin alfa, sPLA2 Inhibitor, Interleukin-7, and Others
• Sepsis Assessment by Product Type
• Sepsis Assessment by Stage and Product Type
• Sepsis Assessment by Route of Administration
• Sepsis Assessment by Stage and Route of Administration
• Sepsis Assessment by Molecule Type
• Sepsis Assessment by Stage and Molecule Type
• Sepsis- Market Drivers and Barriers

Table of Content

1. Introduction
2. Executive Summary
3. Sepsis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sepsis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Sepsis Collaboration Deals
9. Late Stage Products (Phase III)
10. Rezafungin: Cidara Therapeutics
11. Mid Stage Products (Phase II)
12. VBI-S: Vivacelle Bio
13. Early Stage Products (Phase I)
14. HY209: Shaperon
15. Early Stage Products (Preclinical)
16. Selinexor: Karyopharm Therapeutics
17. Inactive Products
18. Sepsis Key Companies
19. Sepsis Key Products
20. Sepsis- Unmet Needs
21. Sepsis- Market Drivers and Barriers
22. Sepsis- Future Perspectives and Conclusion
23. Sepsis Analyst Views
24. Sepsis Key Companies
25. Appendix

Learn more about the emerging therapies of the Sepsis Pipeline Report- Sepsis Treatment

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/